JWA
BCRX icon

JFS Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

JFS Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40
Closed -$204 – 1987
2024
Q1 		$204 Buy
40
+5
+14% +$28 ﹤0.01% 1893
2023
Q4 		$210 Sell
35
-33
-49% -$191 ﹤0.01% 1898
2023
Q3 		$482 Buy
68
+15
+28% +$108 ﹤0.01% 1754
2023
Q2 		$374 Buy
53
+29
+121% +$233 ﹤0.01% 1799
2023
Q1 		$201 Sell
24
-34
-59% -$327 ﹤0.01% 1828
2022
Q4 		$666 Sell
58
-3
-5% -$37 ﹤0.01% 1685
2022
Q3 		$1K Buy
61
+32
+110% +$412 ﹤0.01% 1482
2022
Q2 		$0 Sell
29
-14
-33% -$144 ﹤0.01% 1738
2022
Q1 		$1K Buy
43
+31
+258% +$497 ﹤0.01% 1579
2021
Q4 		$0 Buy
+12
New +$159 ﹤0.01% 1715

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JFS Wealth Advisors's BCRX Position: Q2 2024 in Review

JFS Wealth Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 40 shares — an estimated $204 sold.

JFS Wealth Advisors first reported a position in BCRX in Q4 2021 and held it in 10 quarters. The position peaked at $1K in Q3 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • JFS Wealth Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • JFS Wealth Advisors sold 40 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $204.
  • JFS Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 10 quarters.
  • JFS Wealth Advisors's BioCryst Pharmaceuticals position peaked at $1K in Q3 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on JFS Wealth Advisors's 13F filing for Q2 2024, filed 15 Jul 2024.